BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Down 26.1% in August

Key Points

• BioStem Technologies, Inc. experienced a significant decline in short interest, dropping 26.1% to 172,600 shares as of August 31st.
• As of now, only 1.0% of the company's shares are short sold, indicating a current short-interest ratio of 0.8 days.
• The company's stock opened at $5.30 and has a market capitalization of $88.78 million with a P/E ratio of 4.65.

BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 172,600 shares, a decline of 26.1% from the August 15th total of 233,700 shares. Based on an average daily volume of 220,100 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.0% of the shares of the stock are short sold. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily volume of 220,100 shares, the days-to-cover ratio is presently 0.8 days.

BioStem Technologies Price Performance

Shares of BSEM stock traded up $0.20 on Friday, reaching $5.16. 68,426 shares of the stock were exchanged, compared to its average volume of 84,322. The stock has a market cap of $86.41 million, a PE ratio of 4.53 and a beta of -0.32. BioStem Technologies has a one year low of $4.79 and a one year high of $28.26. The stock has a 50 day moving average price of $8.45 and a 200 day moving average price of $10.72.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.